Perspective on the development of new agents in thoracic cancers

Research output: Contribution to journalArticle


The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM). Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.

Original languageEnglish (US)
Pages (from-to)S27-S28
JournalLung Cancer
Issue numberSUPPL. 1
StatePublished - Jan 1 2005


  • Antimetabolite
  • Lung cancer
  • Malignant pleural mesothelioma
  • Non-small-cell lung cancer
  • Pemetrexed
  • Thoracic cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Perspective on the development of new agents in thoracic cancers'. Together they form a unique fingerprint.

  • Cite this